EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes

Clinical & Experimental Ophthalmology · 2026-05 · 54 (4) · 500-506

DOI: 10.1111/ceo.70072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 08.02.2026. Verfasst von Mark Gillies und 8 weiteren Autor:innen. Beteiligte Einrichtung: Save Sight Institute, The Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Visual Acuity, Angiogenesis Inhibitors, Wet Macular Degeneration. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Bayer, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD).

Methods

A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 were included. Controls were treatment‐naïve eyes starting with aflibercept 2 mg before 2022. Visual acuity ( VA ), macular neovascularisation activity, time to first inactivity, number of injections, injection intervals and number of visits at 12 months were investigated. Eyes treated with faricimab versus aflibercept 2 mg were compared using overlap weighting. The main outcome measure was the 12‐month VA change.

Results

Twenty‐three practitioners treated 160 eyes with a 4‐letter gain in VA (mean, 61.5–65.5 letters) and 48% attaining a dosing interval of ≥ 12 weeks, although 22% were still treated at < 8 weekly intervals. The small proportion (6.9%) of eyes switching to another agent had improved vision but were mostly active when switching off faricimab. Eyes received 7.2 injections (mean) at 7.4 visits (mean), receiving treatment at 98% of visits indicating a strongly proactive treatment regimen. Most (71%) lesions became inactive by 12 months with a mean time to inactivation of 10.3 weeks. Eyes starting faricimab had a significantly higher inactivation rate with more eyes reaching the last injection interval of ≥ 12 weeks than those starting aflibercept 2 mg.

Conclusions

These findings indicate that faricimab is safe and effective for treatment‐naive eyes with nAMD . Faricimab had a stronger effect on nAMD lesion activity than aflibercept 2 mg.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityAngiogenesis InhibitorsWet Macular DegenerationHumansRetrospective StudiesIntravitreal InjectionsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsFemaleAustraliaTreatment OutcomeMaleAgedVascular Endothelial Growth Factor AAged, 80 and overRegistriesFollow-Up StudiesTomography, Optical CoherenceAntibodies, Bispecific

Stichwörter der Autor:innen

faricimabneovascular age‐related macular degenerationobservational studyreal‐world outcomesvascular endothelial growth factor inhibitors

Substanzen

Angiogenesis InhibitorsafliberceptReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • Save Sight Institute, The Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
  • The Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia.
  • Croydon Eye Clinic, Croydon, Victoria, Australia.
  • Marsden Eye Specialists, Parramatta, New South Wales, Australia.
  • Canberra Health Services, Blink Eye & Vision Clinics, University of Canberra, University of Sydney, Sydney, New South Wales, Australia.
  • Coastwide Eye Surgery, Erina, New South Wales, Australia.

Förderung

  • National Health and Medical Research Council
  • Bayer
  • Roche
  • Macular Disease Foundation Australia

Zitieren

APA

Gillies, M., Hashimoto, Y., Nazari, R., Arnold, J., Wang, B., Barry, R., Ferrier, R., Game, J., & Barthelmes, D. (2026). Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia. Clinical & Experimental Ophthalmology, 54(4), 500-506. https://doi.org/10.1111/ceo.70072

Vancouver

Gillies M, Hashimoto Y, Nazari R, Arnold J, Wang B, Barry R, et al. Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia. Clinical & Experimental Ophthalmology. 2026;54(4):500-506. doi:10.1111/ceo.70072

BibTeX
@article{Gillies2026,
  author = {Gillies, Mark and Hashimoto, Yohei and Nazari, Rahman and Arnold, Jennifer and Wang, Beibei and Barry, Richard and Ferrier, Ross and Game, Justin and Barthelmes, Daniel},
  title = {Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2026},
  volume = {54},
  number = {4},
  pages = {500--506},
  doi = {10.1111/ceo.70072}
}
Kostenlos starten →